COMMUNIQUÉS West-GlobeNewswire

Virbac : Rapport Annuel Virbac au 31 décembre 2025 (ESEF)
27/04/2026
Veuillez trouver le Rapport Annuel du Groupe au format ESEF au 31 décembre 2025 Pièce jointe Rapport_Annuel_Virbac_2025_XBRL
Virbac : Public release of Virbac Annual Report at 31 December 2025.
27/04/2026
Public release of Virbac Annual Report at 31 December 2025. The Group released and filed its 2025 Annual Report with the French “Autorité des marchés financiers”, at the ESEF format. Additionally, the report is attached [...]
Virbac : Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025
27/04/2026
Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au format [...]
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
27/04/2026
PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its financial creditors [...]
AB Science annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers
27/04/2026
COMMUNIQUE DE PRESSE AB SCIENCE annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers AB Science est parvenue à un accord définitif avec [...]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
27/04/2026
Ghent, Belgium, April 27, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE - REGULATED INFORMATION 27 April 2026, 6:00 pm CEST Ghent, Belgium, 27 April 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " [...]
IBA – ACQUISITION OF OWN SHARES
27/04/2026
Louvain-la-Neuve, Belgium, April 27 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
IBA – ACQUISITION D’ACTIONS PROPRES
27/04/2026
Louvain-la-Neuve, Belgique, 27 avril 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance
27/04/2026
Global CDMO recognized for exceptional quality systems and regulatory track record; named finalist in Excellence in Client Service & Partnership and Manufacturing Operations categories SEATTLE, April 27, 2026 (GLOBE [...]
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
27/04/2026
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
27/04/2026
Déclaration de transactions sur actions propres Paris, France (27 avril 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 24 avril 2026, les [...]
NEXGEL Appoints Ian Blackman as Chief Financial Officer
27/04/2026
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company [...]
TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026
27/04/2026
Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System FREDERICK, Md., April 27, 2026 (GLOBE NEWSWIRE [...]
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
27/04/2026
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market [...]
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
27/04/2026
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04’s role in providing a treatment option for patients where existing treatments inadequately [...]
IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026
27/04/2026
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026 [...]
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
27/04/2026
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya’s Work with Patients to Advance [...]
TerrAscend Announces Preliminary First Quarter 2026 Financial Results and Schedules Earnings Conference Call
27/04/2026
First Quarter 2026 Net Revenue Totaled $65.5 million with Gross Profit Margin of 52.8% TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading [...]
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
27/04/2026
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari’s global intellectual property across all major [...]

Pages